EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?

Alessandro Maloberti, Valentina Colombo, Francesca Daus, Lorenzo De Censi, Maurizio Giuseppe Abrignani, Pier Luigi Temporelli, Giulio Binaghi, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, Claudio Borghi, Fabrizio Oliva

Nutrition, Metabolism and Cardiovascular Diseases · 2025

DOI: 10.1016/j.numecd.2024.103792 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2025. Verfasst von Alessandro Maloberti und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; Cardiology 4, Cardio Center, ASST GOM Niguarda Ca' Granda, Milan, Italy. …. Hauptthemen laut MEDLINE: Uric Acid, Cardiovascular Diseases, Hyperuricemia, Gout Suppressants. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The most frequent consequence of elevated uric acid (UA) levels is the development of gout and urate kidney disease. Besides these effects, several studies have investigated the association between hyperuricemia and cardiovascular (CV) disease. High serum UA has been identified as an important determinant of all-cause and CV mortality and CV events (acute and chronic coronary syndrome, stroke and peripheral artery disease). Despite the high number of publications on this topic, there are two questions that are still unanswered: do we need a specific CV cut-off of serum UA to better refine the CV risk? Is urate lowering treatment (ULT) able to reduce CV risk in asymptomatic patients? In this review, we will focus on these two points. DATA SYNTHESIS: Although no doubt exists that the relationship between CV events starts at lower levels than the actually used cut-off, different papers found dissimilar cut-offs. Furthermore, heterogeneity is present depending on the specific CV events evaluated and none of the found cut-off have been tested in external populations (in order to confirm its discriminatory capacity). Furthermore, only few randomized clinical trials on the role of hypouricemic agents in reducing the CV risk have been published giving heterogeneous results. The last published one (ALL-HEART) has strong limitations, that we will deeply discuss. CONCLUSIONS: A definitive answer to the two questions is impossible with the actually published paper but, over identifying current gaps in knowledge we try to individuate how they can be overruled.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uric AcidCardiovascular DiseasesHyperuricemiaGout SuppressantsHumansBiomarkersRisk AssessmentHeart Disease Risk FactorsTreatment OutcomePredictive Value of TestsProtective Factors

Stichwörter der Autor:innen

Cardiovascular riskHyperuricemiaHypouricemic therapiesUric acid

Substanzen

Uric AcidBiomarkersGout Suppressants

Autor:innen und Institutionen

  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; Cardiology 4, Cardio Center, ASST GOM Niguarda Ca' Granda, Milan, Italy. Electronic address: alessandro.maloberti@unimib.it.
  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Operative Unit of Cardiology, P. Borsellino Hospital, 91025, Marsala, Italy.
  • Division of Cardiac Rehabilitation, ICS Maugeri, IRCCS, Gattico-Veruno, Italy.
  • Cardiology Unit, ARNAS G. Brotzu, Cagliari, Italy.
  • Clinical and Rehabilitative Cardiology, San Filippo Neri Hospital, ASL Rome 1, Rome, Italy.

Zitieren

APA

Maloberti, A., Colombo, V., Daus, F., De Censi, L., Abrignani, M. G., Temporelli, P. L., Binaghi, G., Colivicchi, F., Grimaldi, M., Gabrielli, D., Borghi, C., & Oliva, F. (2025). Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2024.103792

Vancouver

Maloberti A, Colombo V, Daus F, De Censi L, Abrignani MG, Temporelli PL, et al. Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?. Nutrition, Metabolism and Cardiovascular Diseases. 2025. doi:10.1016/j.numecd.2024.103792

BibTeX
@article{Maloberti2025,
  author = {Maloberti, Alessandro and Colombo, Valentina and Daus, Francesca and De Censi, Lorenzo and Abrignani, Maurizio Giuseppe and Temporelli, Pier Luigi and Binaghi, Giulio and Colivicchi, Furio and Grimaldi, Massimo and Gabrielli, Domenico and Borghi, Claudio and Oliva, Fabrizio},
  title = {Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.numecd.2024.103792}
}
Kostenlos starten →